Teva Pharmaceutical Industries Limited (TEVA) Announces Launch of Generic Avapro® and Generic Avalide® in the United States; Awarded 180-Day Period of Marketing Exclusivity  
4/2/2012 10:27:06 AM

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it has commenced commercial launch of both Irbesartan and Irbesartan-Hydrochlorothiazide Tablets, the Company’s generic versions of Sanofi Aventis’ high blood pressure treatments, Avapro® and Avalide® Tablets. The brand products had annual sales of approximately $464 million and $124 million, respectively, in the United States, based on IMS sales data.